Functional consequence of MDR1 expression on imatinib intracellular concentrations

In their recent article, Mahon et al[1][1] demonstrate that MDR1 gene overexpression can confer resistance to imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) in leukemia cell lines. Several other cellular mechanisms of resistance to imatinib have also been identified,[2][2]-[4][3] but the